NASDAQ · KZIA
Kazia Therapeutics Ltd ADR
$8.72+$0.39 (+4.68%)
Kazia Therapeutics Ltd ADR’s quoted price sits in the lower half of its reported 52-week range, 49.89% below the high.
Loading market information…
AMEX · OGEN · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Oragenics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 70.99% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Oragenics, Inc.’s next earnings report is currently expected on Nov 16, 2026, with estimated earnings per share of -$90.00. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Oragenics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Oragenics, Inc. (OGEN) is a U.S.-based biotechnology firm primarily focused on creating treatments for infectious diseases. Among its pipeline assets are two vaccine candidates designed to combat the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2): NT-CoV2-1, an intranasal formulation, and Terra CoV-2, an intramuscular option. Beyond its infectious disease focus, Oragenics also has other experimental treatments under development, including LPT3-04, targeting weight loss, and SMaRT Replacement Therapy, a topical solution aimed at preventing dental cavities. Strategic alliances are also a part of its operations. This includes a licensing deal with Noachis Terra Inc. for patents and biological resources related to pre-fusion coronavirus spike proteins. Additionally, Oragenics is collaborating with Precigen, Inc. and ILH Holdings, Inc. on the advancement and market introduction of MU1140 and its associated compounds. Established in 1996, the company, formerly known as Oragen, Inc., maintains its headquarters in Tampa, Florida.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:27 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q3 2024 |
|---|
| Nov 13, 2024 |
| -$11.41+87.32% vs estimate |
| $100.00K |
THE ANALYST VIEW
3 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$8.72+$0.39 (+4.68%)
Kazia Therapeutics Ltd ADR’s quoted price sits in the lower half of its reported 52-week range, 49.89% below the high.
$0.44-$0.01 (-3.16%)
Ensysce Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.36% below the high.
$0.37-$0.01 (-1.55%)
Soligenix, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.28% below the high.
$4.77+$0.26 (+5.76%)
CNS Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.74% below the high.
$0.16-$0.00 (-2.42%)
AIM ImmunoTech Inc.’s quoted price sits in the lower half of its reported 52-week range, 93.03% below the high.
$3.21+$0.17 (+5.59%)
Qualigen Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.56% below the high.
$2.12+$0.02 (+0.95%)
Xenetic Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.09% below the high.
$0.18-$0.00 (-2.67%)
KALA BIO, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.82% below the high.
